Skip to main content

Table 4 Characteristics of patients with definite and probable stent thrombosis

From: High platelet reactivity affects the clinical outcomes of patients undergoing percutaneous coronary intervention

Case Risk factors Lesions Stent number AA-MAR, % ADP-MAR, % CYP2C19 gene Use of antiplatelet drugs Time from PCI to stent thrombosis (days) Cardiac death
1 EH Multi-vessel disease 2 15.4 60.6 NA Dual-antiplatelet for 2 years 2 0
2 Smoking Left main lesion 3 42.9 60.3 NA Dual-antiplatelet for 2 years 241 1
3 EH, DM, smoking Multi-vessel disease 8 35 58.4 Poor metabolizer Dual-antiplatelet for 2 years 170 0
4 EH, smoking Multi-vessel disease 3 20 58.6 NA Dual-antiplatelet for 2 years 1 0
5 DM Multi-vessel disease 3 79.8 67.9 NA Clopidogrel for lifelong time, aspirin for half year 236 1
6 EH, smoking Pro-LAD lesion 1 50 60.5 Intermediate metabolizer Clopidogrel for 1 year, aspirin stopped by oneself at 1 month after procedure, and aspirin re-used at 1 year 455 0
7 EH Multi-vessel disease 3 20.2 63 Intermediate metabolizer Aspirin for lifelong time, clopidogrel for 1 year 12 0
8 EH, DM Multi-vessel disease 2 39 58.7 Intermediate metabolizer Dual-antiplatelet for 2 years 82 0
9 No Multi-vessel disease + left main lesion 3 49.8 61.1 NA Dual-antiplatelet for 2 years 94 1
10 EH, DM Multi-vessel disease + left main lesion 6 37 45 Poor metabolizer Dual-antiplatelet for 2 years 1 0
11 DM, smoking Multi-vessel disease 4 24.6 56.4 Poor metabolizer Dual-antiplatelet for 2 years 731 1
12 EH, DM, smoking, CKD 4 Multi-vessel disease + left main lesion 7 21.1 68 Intermediate metabolizer Dual-antiplatelet for 2 years 617 1
13 Smoking Multi-vessel disease 2 34.6 57.2 Intermediate metabolizer Dual-antiplatelet for 2 years 42 1
14 EH Multi-vessel disease 6 45.4 60.3 Intermediate metabolizer Dual-antiplatelet for 2 years 138 1
  1. EH essential hypertension, DM diabetes mellitus, CKD chronic kidney disease, LAD left anterior descending, AA arachidonic acid, MAR maximal aggregation ratio, ADP adenosine diphosphate, PCI percutaneous coronary intervention